GSK Can’t Get High Court Review In Avandia Marketing Fight

Christel Deskins

Law360 (October 5, 2020, 5:17 PM EDT) — The U.S. Supreme Court will not take up an appeal by GlaxoSmithKline in its bid to overturn a Third Circuit decision forcing it to face a suit over the marketing of diabetes medication Avandia, the high court announced Monday. As is custom, […]

Law360 (October 5, 2020, 5:17 PM EDT) — The U.S. Supreme Court will not take up an appeal by GlaxoSmithKline in its bid to overturn a Third Circuit decision forcing it to face a suit over the marketing of diabetes medication Avandia, the high court announced Monday.

As is custom, the justices did not state their reasoning for denying the appeal. According to court documents, the health plans that brought the suit waived their right to respond to GSK’s petition in July.

The denial sends the suit back to district court, where health plans like those offered by United Food and Commercial Workers Local 1776 alleged GSK conducted a…

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Source Article

Next Post

Ghana suspends gold royalty fund's London listing -finance ministry letter

ACCRA, Oct 6 (Reuters) – Ghana has suspended the $500 million listing of its gold royalty fund Agyapa Royalties in London following concerns raised by the main opposition party about transparency and governance, a finance ministry letter reviewed by Reuters showed. In an Oct. 1 letter to the special prosecutor, […]